睿知中国医院研究地图
候选清单

长沙中南大学湘雅

中南大学湘雅二医院

Second Xiangya Hospital

在本站收录的 53 种疾病中,这家医院列在其中 34 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

中南大学湘雅二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma25 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma6 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma55 篇牵头论文
  4. 胃癌Stomach cancer32 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma2 篇牵头论文
  7. 骨肉瘤Osteosarcoma43 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma5 篇牵头论文
  10. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma14 篇牵头论文
  12. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia3 篇牵头论文
  13. 再生障碍性贫血Aplastic anaemia6 篇牵头论文
  14. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  15. β 地中海贫血Beta thalassaemia2 篇牵头论文
  16. 血友病 AHaemophilia A1 篇牵头论文
  17. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  18. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  19. 范可尼贫血Fanconi anaemia5 篇牵头论文
  20. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder7 篇牵头论文
  21. IgG4相关性疾病IgG4-related disease1 篇牵头论文
  22. 重症肌无力Myasthenia gravis6 篇牵头论文
  23. 肝豆状核变性Wilson disease7 篇牵头论文
  24. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis3 篇牵头论文
  25. 大动脉炎Takayasu arteritis5 篇牵头论文
  26. 特发性肺纤维化Idiopathic pulmonary fibrosis18 篇牵头论文
  27. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis3 篇牵头论文
  28. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  29. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  30. 白塞病Behçet disease1 篇牵头论文
  31. IgA 肾病IgA nephropathy14 篇牵头论文
  32. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  33. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  34. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、烟雾病、胆道闭锁、肝包虫病、脊髓性肌萎缩症、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 1.1%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 3320232024: 8820242025: 992025

长沙有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术影像与人工智能免疫治疗
论文中的科室病理/检验科肿瘤内科耳鼻喉/头颈外科肾内科

这些论文过半是实验室或动物研究。

牵头的论文25
  1. A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma.2026Cancer science免费全文
  2. Programmed cell death in nasopharyngeal carcinoma: Mechanisms and therapeutic targets.2025Biochimica et biophysica acta. Reviews on cancer
  3. Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma.2025Cell death & disease免费全文
  4. The Combined Treatment of 4EGl-1 and MK-2206 Inhibits Nasopharyngeal Carcinoma Progress by Inducing Autophagy.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. SSTR2 exhibits a positive correlation with PD-L1 and predicts poor prognosis in nasopharyngeal carcinoma.2025International immunopharmacology
  6. Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma.2025Journal of translational medicine免费全文
  7. Unveiling immune resistance mechanisms in nasopharyngeal carcinoma and emerging targets for antitumor immune response: tertiary lymphoid structures.2025Journal of translational medicine免费全文
  8. Nomograms Based on Blood-Based Biomarkers for Predicting Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients.2025Mediators of inflammation免费全文
  9. Deep learning based analysis of G3BP1 protein expression to predict the prognosis of nasopharyngeal carcinoma.2025PloS one免费全文
  10. Nasogastric tube nutrition support enhances chemoradiotherapy compliance and alleviates mucosal reactions in nasopharyngeal carcinoma: a 856-case retrospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  11. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.2024Cell communication and signaling : CCS免费全文
  12. Predicting the overall survival and progression-free survival of nasopharyngeal carcinoma patients based on hemoglobin, albumin, and globulin ratio and classical clinicopathological parameters.2024Head & neck
  13. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  14. G3BP1 Interact with JAK2 mRNA to Promote the Malignant Progression of Nasopharyngeal Carcinoma via Activating JAK2/STAT3 Signaling Pathway.2024International journal of biological sciences免费全文
  15. SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma.2024Journal of clinical pathology免费全文
  16. Comparative Proteomics Identified EXOSC1 as a Target Protein of Anticancer Peptide LVTX-8 in Nasopharyngeal Carcinoma Cells.2024Journal of proteome research
  17. LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  18. Nomograms based on the lymphocyte-albumin-neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy.2024Scientific reports免费全文
  19. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.2023BMJ open免费全文
  20. CircLASP1 silence strengthens the therapeutic effects of MK-2206 on nasopharyngeal cancer through upregulating miR-625.2023Cancer science免费全文
  21. Prognostic value of the fibrinogen albumin ratio index (FARI) in nasopharyngeal carcinoma patients undergoing radiotherapy.2023Scientific reports免费全文
  22. Circ_0000523 regulates miR-1184/COL1A1/PI3K/Akt pathway to promote nasopharyngeal carcinoma progression.2022Apoptosis : an international journal on programmed cell death
  23. Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.2022International journal of biological sciences免费全文
  24. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.2022Scientific reports免费全文
  25. YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.2022Scientific reports免费全文
中文论文(未计入)1
  1. Prognostic value of pretreatment peripheral blood hemoglobin×lymphocyte/monocyte ratio in patients with nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  2. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors已完成NCT04215978研究中心I期2020-01 启动
  3. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  4. A Trial of Endostar in Patients With Carcinoma of the Head and Neck状态不明NCT02902432研究中心II期2016-06 启动
PubMed 以外找到的论文(未计入)30
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  3. CircARHGAP12 suppresses cisplatin-induced alkaliptosis in nasopharyngeal carcinoma through G3BP1-mediated upregulation of CA9 in an RNA G-quadruplex-dependent manner2025Research Square预印本
  4. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  5. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  6. Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.2024Journal of Clinical Oncology会议摘要
  7. RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA2024Research Square预印本
  8. Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19.2023Journal of Clinical Oncology会议摘要
  9. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023未列出期刊其他
  10. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  11. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figshare数据集
  12. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  13. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  14. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  15. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  16. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  17. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  18. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  19. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  20. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  21. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  22. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  23. Fabrication of metformin and survivin siRNA encapsulated into polyethyleneimine-altered silk fibroin nanoparticles for the treatment of nasopharyngeal carcinoma2022Process Biochemistry论文
  24. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要
  25. Additional file 1 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figshare数据集
  26. Additional file 2 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figshare数据集
  27. Combination of CD47 Expression and SIRI as a Prognostic Factor in Nasopharyngeal Carcinoma Patients2021Research Square预印本
  28. Elevated transcriptional pausing of RNA polymerase II underlies acquired resistance to radiotherapy2021bioRxiv (Cold Spring Harbor Laboratory)预印本
  29. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  30. [Retracted] MicroRNA‑19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 22021Experimental and Therapeutic Medicine论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 1120232024: 0020242025: 002025

长沙有 3 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题免疫治疗分子标志物与基因
论文中的科室消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles carrying miR-655-3p inhibit the development of esophageal cancer by regulating the expression of HIF-1α via a LMO4/HDAC2-dependent mechanism.2023Cell biology and toxicology
  2. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.2022Biochemical and biophysical research communications
  3. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.2022Frontiers in public health免费全文
  4. Network analysis of genes associated with esophageal squamous cell carcinoma progression.2022Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  5. FBX4 mediates rapid cyclin D1 proteolysis upon DNA damage in immortalized esophageal epithelial cells.2021Biochemical and biophysical research communications
  6. Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation.2021Journal of cellular physiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
PubMed 以外找到的论文(未计入)5
  1. 470eP Multimodal imaging–clinical modeling to predict pathologic response after neoadjuvant chemoimmunotherapy for resectable ESCC2025Annals of Oncology论文
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 55 篇,占 0.4%。

牵头论文
55
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 9920222023: 151520232024: 111120242025: 11112025

长沙有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-11
    登记号
    NCT07209813

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南京、南昌、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后局部治疗(消融、TACE、HAIC)免疫与靶向药物
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科消化/肝病科
牵头的论文55
  1. Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth.2026Journal of advanced research免费全文
  2. Comparison of Diagnostic Accuracies of Radiomics and Non-radiomics Model for Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2025Academic radiology
  3. High Fibroblast Activation Protein Expression in Hepatocellular Carcinoma: CT Imaging Features and Histological Characteristics.2025Academic radiology
  4. The Role of ROS and Its Sources in Tumorigenesis: Friend or Foe?2025Advanced biology
  5. ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  6. SLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling.2025Analytical cellular pathology (Amsterdam)免费全文
  7. Synthesis and biological evaluation of 4-((3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline derivatives as novel potential transforming growth factor-β type 1 receptor inhibitors for hepatocellular carcinoma.2025Bioorganic chemistry
  8. Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma.2025Cancer gene therapy免费全文
  9. RAB40C recruiting TRIM21 facilitates the progression of hepatocellular carcinoma by stabilizing EGFR.2025Cell communication and signaling : CCS免费全文
  10. The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  11. Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis.2025PloS one免费全文
  12. Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma.2025World journal of surgical oncology免费全文
  13. CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.2024Biochimica et biophysica acta. Molecular basis of disease
  14. TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.2024Cancer science免费全文
  15. Genomic and immune landscape in hepatocellular carcinoma: Implications for personalized therapeutics.2024Environmental toxicology
  16. METTL5 enhances the mRNA stability of TPRKB through m6A modification to facilitate the aggressive phenotypes of hepatocellular carcinoma cell.2024Experimental cell research
  17. Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.2024Frontiers in immunology免费全文
  18. Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?2024Hepatology (Baltimore, Md.)
  19. A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  20. Identification of the Roles of Coagulation-related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy.2024Recent patents on anti-cancer drug discovery
  21. Subcutaneous adipose tissue/neutrophil-to-lymphocyte ratio is a potential biomarker in patients with hepatocellular carcinoma undergoing liver resection.2024Science progress免费全文
  22. Circular RNA DNAH14 molecular mechanism in an experimental model of hepatocellular carcinoma treated with Cobalt chloride to mimic the hypoxia-like response of transcatheter arterial chemoembolization.2024Scientific reports免费全文
  23. Robotic anatomical resection for hepatocellular carcinoma located within segment 7 using the Glissonean approach.2024Updates in surgery
  24. Letter: repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma in ideal candidates - authors' reply.2023Alimentary pharmacology & therapeutics
  25. Editorial: is microwave ablation an alternative to liver resection for hepatocellular carcinoma? Authors' reply.2023Alimentary pharmacology & therapeutics
  26. An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection.2023Annals of surgical oncology
  27. ASO Author Reflections: The FIBA Score-A Novel Scoring System to Predict Outcomes in Hepatocellular Carcinoma After Surgical Resection or Transarterial Chemoembolization.2023Annals of surgical oncology免费全文
  28. Mechanism underlying the effect of Pulsatilla decoction in hepatocellular carcinoma treatment: a network pharmacology and in vitro analysis.2023BMC complementary medicine and therapies免费全文
  29. Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.2023BMC medicine免费全文
  30. TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication.2023Cancer gene therapy
  31. SLC12A5 promotes hepatocellular carcinoma growth and ferroptosis resistance by inducing ER stress and cystine transport changes.2023Cancer medicine免费全文
  32. Development and investigation of metabolism-associated risk assessment models for patients with viral hepatitis.2023Frontiers in cellular and infection microbiology免费全文
  33. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.2023Frontiers in immunology免费全文
  34. Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.2023Functional & integrative genomics
  35. Association between antihypertensive drugs and hepatocellular carcinoma: A trans-ancestry and drug-target Mendelian randomization study.2023Liver international : official journal of the International Association for the Study of the Liver
  36. Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.2023Pharmacological research
  37. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.2023PloS one免费全文
  38. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization.2023Radiology
  39. Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern.2022Abdominal radiology (New York)免费全文
  40. Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability of treatment weighting analysis.2022Alimentary pharmacology & therapeutics
  41. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma.2022BMC medicine免费全文
  42. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.2022Cancer letters免费全文
  43. A novel DNA methylation-driver gene signature for long-term survival prediction of hepatitis-positive hepatocellular carcinoma patients.2022Cancer medicine免费全文
  44. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.2022Cell reports
  45. Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.2022Frontiers in immunology免费全文
  46. A Risk Model Developed Based on Necroptosis Predicts Overall Survival for Hepatocellular Carcinoma and Identification of Possible Therapeutic Drugs.2022Frontiers in immunology免费全文
  47. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma.2022Gene
  48. A predictive model of incomplete response after transarterial chemoembolization for early or intermediate stage of hepatocellular carcinoma: consideration of hepatic angiographic and cross-sectional imaging.2021Abdominal radiology (New York)
  49. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.2021Drug delivery免费全文
  50. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.2021Immunotherapy
  51. The roles and mechanisms of hypoxia in liver fibrosis.2021Journal of translational medicine免费全文
  52. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.2021Journal of vascular and interventional radiology : JVIR
  53. Intra-platelet serotonin and YAP contributed to poor prognosis of hepatocellular carcinoma.2021Life sciences
  54. Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion.2021Medicine免费全文
  55. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.2021Theranostics免费全文
中文论文(未计入)4
  1. Research progress in cuproptosis in liver cancer.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. Role of miR-5010-3p in predicting the prognosis of hepatocellular carcinoma.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  3. Regulatory effect of PINK1/Parkin axis on mitophagy in isoniazide-induced hepatocellular injury.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  4. Mn-SOD alleviates methotrexate-related hepatocellular injury via GSK-3β affecting anti-oxidative stress of HO-1 and Drp1.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07209813研究中心II期2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 0.3%。

牵头论文
32
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 7720222023: 6620232024: 6620242025: 332025

长沙有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题早期发现与内镜影像与人工智能腹膜转移与晚期
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科
牵头的论文32
  1. FTO Upregulates GLG1 Expression via m6A Methylation Modification to Facilitate Gastric Cancer Cell Migration and Invasion.2026Journal of gastroenterology and hepatology
  2. Association between metabolic syndrome and prognosis in elderly gastric cancer patients.2025Geriatric nursing (New York, N.Y.)
  3. Brucine Inhibits Gastric Cancer via Activation of Ferroptosis Through Regulating the NF-κB Signaling Pathway.2025Journal of biochemical and molecular toxicology
  4. Endoscopic ultrasound-guided bite-on-bite biopsy and endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of gastric tumors with negative malignant endoscopy biopsies: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  5. Silencing immune-infiltrating biomarker CCDC80 inhibits malignant characterization and tumor formation in gastric cancer.2024BMC cancer免费全文
  6. Circ_PABPC1 promotes the malignancy of gastric cancer through interacting with ILK to activate NF-κB pathway.2024Experimental cell research
  7. Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.2024Frontiers in immunology免费全文
  8. Exosomal miR-502-5p suppresses the progression of gastric cancer by repressing angiogenesis through the Wnt/β-catenin pathway.2024Irish journal of medical science
  9. Personalizing age of gastric cancer screening based on comorbidity in China: Model estimates of benefits, affordability and cost-effectiveness optimization.2024Preventive medicine
  10. Lesion size affects the risk of technical difficulty in gastric endoscopic submucosal dissection.2024Scientific reports免费全文
  11. Explore the active ingredients and potential mechanisms of JianPi QingRe HuaYu Methods in the treatment of gastric inflammation-cancer transformation by network pharmacology and experimental validation.2023BMC complementary medicine and therapies免费全文
  12. SMC1A facilitates gastric cancer cell proliferation, migration, and invasion via promoting SNAIL activated EMT.2023BMC gastroenterology免费全文
  13. The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS.2023BMC gastroenterology免费全文
  14. Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  15. Circular RNA circPOFUT1 enhances malignant phenotypes and autophagy-associated chemoresistance via sequestrating miR-488-3p to activate the PLAG1-ATG12 axis in gastric cancer.2023Cell death & disease免费全文
  16. AGAP2-AS1 promotes the assembly of m6A methyltransferases and activation of the IL6/STAT3 pathway by binding with WTAP in the carcinogenesis of gastric cancer.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  17. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.2022BMJ open免费全文
  18. Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.2022Frontiers in public health免费全文
  19. Long non-coding RNA SNHG1/microRNA-195-5p/Yes-associated protein axis affects the proliferation and metastasis of gastric cancer via the Hippo signaling pathway.2022Functional & integrative genomics
  20. Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis.2022Genetics research免费全文
  21. LncRNA NR2F2-AS1 functions as a tumor suppressor in gastric cancer through targeting miR-320b/PDCD4 pathway.2022Histology and histopathology
  22. Kinesin family member 2A links with advanced tumor stage, reduced chemosensitivity and worse prognosis in gastric cancer.2022Journal of clinical laboratory analysis免费全文
  23. Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.2022PharmacoEconomics
  24. STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer.2021Acta biochimica et biophysica Sinica
  25. Expression and prognosis analyses of BUB1, BUB1B and BUB3 in human sarcoma.2021Aging免费全文
  26. The prognostic value of circular RNA regulatory genes in competitive endogenous RNA network in gastric cancer.2021Cancer gene therapy
  27. LINC01133 hampers the development of gastric cancer through increasing somatostatin via binding to microRNA-576-5p.2021Epigenomics
  28. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.2021Journal of immunology research免费全文
  29. Efficacy and safety of submucosal tunneling endoscopic resection for gastric submucosal tumors: a systematic review and meta-analysis.2021Revista espanola de enfermedades digestivas
  30. Factors that predict the technical difficulty during endoscopic full-thickness resection of a gastric submucosal tumor.2021Revista espanola de enfermedades digestivas
  31. Factors predicting technical difficulties during endoscopic submucosal excavation for gastric submucosal tumor.2021The Journal of international medical research免费全文
  32. Value of HMGB1 expression for assessing gastric cancer severity: a systematic meta-analysis.2021The Journal of international medical research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  2. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  3. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  4. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer状态不明NCT03273920研究中心不分期2017-09 启动
  5. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 6 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文1
  1. Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells.2022Cell death & disease
早期论文(2016–2020 年)2
  1. Case Report: Adult Retinoblastoma Progression in 19 Months.2020Optometry and vision science : official publication of the American Academy of Optometry
  2. MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation.2018Journal of cellular biochemistry
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma状态不明NCT04990271研究中心II期2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 6 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
牵头的论文2
  1. Letter: Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery.2022Neurosurgery
  2. Letter to the editor of radiotherapy and oncology regarding the article "Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan" by Demizu et al.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
早期论文(2016–2020 年)19
  1. The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.2019Neurosurgery
  2. Clinicopathological and Prognostic Characteristics in Extra-Axial Chordomas: An Integrative Analysis of 86 Cases and Comparison With Axial Chordomas.2019Neurosurgery
  3. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.2019Neurosurgery
  4. Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.2018Cancer immunology, immunotherapy : CII
  5. Letter to the Editor. Brachyury as prognostic biomarker in chordoma.2018Journal of neurosurgery
  6. CDK4 expression in chordoma: A potential therapeutic target.2018Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  7. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014.2018Journal of orthopaedic surgery and research
  8. Letter: Cranial Chordoma: A New Preoperative Grading System.2018Neurosurgery
  9. Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients.2018World neurosurgery
  10. Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.2018World neurosurgery
  11. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.2017Biochemical and biophysical research communications
  12. Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  13. Letter to the Editor: Influence of age on survival outcomes in patients with spinal chordoma.2017Journal of neurosurgery. Spine
  14. Prognostic factors in spinal chordoma: An update of current systematic review and meta-analysis.2017Journal of surgical oncology
  15. Letter: Factors Predicting Recurrence after Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities.2017Neurosurgery
  16. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.2017Neurosurgery
  17. Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature.2017World neurosurgery
  18. Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis.2017World neurosurgery
  19. Prognostic Biomarkers in Spinal Chordoma: A Systematic Review.2016Journal of neuropathology and experimental neurology

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 43 篇,占 1.9%。

牵头论文
43
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 131320222023: 2220232024: 111120242025: 882025

长沙有 10 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科病理/检验科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文43
  1. Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization.2026Advanced materials (Deerfield Beach, Fla.)
  2. Targeting Mitochondrial Oxidative Stress by Calcium/Copper/Elesclomol Tri-Overloaded Nanocages for Osteosarcoma Immunotherapy via Immunogenic Cell Death.2025ACS nano
  3. Assembly of a biomimetic copper-based nanocomplex for alleviating hypoxia to enhance cuproptosis against osteosarcoma and lung metastasis.2025Acta biomaterialia
  4. A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  5. RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  6. Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU+ Endothelial Cells as Key Players in Tumor Progression.2025Cancer science
  7. Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma.2025International immunopharmacology
  8. Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma.2025Oncogene
  9. PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.2025Signal transduction and targeted therapy
  10. Endoprosthetic replacement with preservation of the epiphysis for proximal tibial reconstruction after osteosarcoma resection in children: a case report.2024BMC musculoskeletal disorders
  11. PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT.2024Cancer research
  12. RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.2024Environmental toxicology
  13. SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  14. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis.2024Frontiers in immunology
  15. The role of disulfidptosis-associated LncRNA-LINC01137 in Osteosarcoma Biology and its regulatory effects on macrophage polarization.2024Functional & integrative genomics
  16. RREB1 could act as an immunological and prognostic biomarker: From comprehensive analysis to osteosarcoma validation.2024International immunopharmacology
  17. Bibliometric analysis and visualisation of research hotspots and frontiers on omics in osteosarcoma.2024Journal of cancer research and clinical oncology
  18. Identification and Validation of a Novel PANoptosis-related Gene Signatured for Osteosarcoma as Prognostic Model.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  19. Radiomics analysis in differentiating osteosarcoma and chondrosarcoma based on T2-weighted imaging and contrast-enhanced T1-weighted imaging.2024Scientific reports
  20. Machine learning survival prediction using tumor lipid metabolism genes for osteosarcoma.2024Scientific reports
  21. The Eph/Ephrin system in primary bone tumor and bone cancer pain.2023Aging
  22. The BRD4-SRPK2-SRSF2 signal modulates the splicing efficiency of ACSL3 pre-mRNA and influences erastin-induced ferroptosis in osteosarcoma cells.2023Cell death & disease
  23. Circ_0003732 promotes osteosarcoma progression through regulating miR-377-3p/CPEB1 axis and Wnt/β-catenin signaling pathway.2022Anti-cancer drugs
  24. Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.2022Cell cycle (Georgetown, Tex.)
  25. Intelligent Segmentation Medical Assistance System for MRI Images of Osteosarcoma in Developing Countries.2022Computational and mathematical methods in medicine
  26. A Residual Fusion Network for Osteosarcoma MRI Image Segmentation in Developing Countries.2022Computational intelligence and neuroscience
  27. Extraosseous Ewing Sarcoma of the Cervical Esophagus: Case Report and Literature Review.2022Ear, nose, & throat journal
  28. Knowledge atlas and emerging trends on ncRNAs of osteosarcoma: A bibliometric analysis.2022Frontiers in endocrinology
  29. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.2022Frontiers in endocrinology
  30. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.2022Frontiers in immunology
  31. Effects of butein on human osteosarcoma cell proliferation, apoptosis, and autophagy through oxidative stress.2022Human & experimental toxicology
  32. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.2022International journal of nanomedicine
  33. Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma.2022Journal of bone and mineral metabolism
  34. The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.2022Journal of hematology & oncology
  35. MicroRNA-143 expression inhibits the growth and the invasion of osteosarcoma.2022Journal of orthopaedic surgery and research
  36. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.2021BMC cancer
  37. The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.2021BMC cancer
  38. The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.2021BMC cancer
  39. Identification of potential micro-messenger RNAs (miRNA-mRNA) interaction network of osteosarcoma.2021Bioengineered
  40. Noncoding RNAs in osteosarcoma: Implications for drug resistance.2021Cancer letters
  41. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation.2021Cell death & disease
  42. Diagnostic and Prognostic Significance of Dysregulated Expression of Circular RNAs in Osteosarcoma.2021Expert review of molecular diagnostics
  43. Long Noncoding RNA HCG9 Promotes Osteosarcoma Progression through RAD51 by Acting as a ceRNA of miR-34b-3p.2021Mediators of inflammation
中文论文(未计入)4
  1. Application and mechanisms of targeting BRD4 in osteosarcoma.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  2. Downregulation of B4GALNT1 inhibits proliferation and metastasis of osteosarcoma cells.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. Curcumin inhibits the proliferation and migration of osteosarcoma by regulating the expression of super-enhancer-associated genes.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  4. [Bioinformatics Analysis on Key Genes and Immune Infiltration of Osteosarcoma].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
早期论文(2016–2020 年)43
  1. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.2020Aging
  2. The regulatory effect of has-circ-0001146/miR-26a-5p/MNAT1 network on the proliferation and invasion of osteosarcoma.2020Bioscience reports
  3. The prognostic role of CD133 expression in patients with osteosarcoma.2020Clinical and experimental medicine
  4. Role of exosomal miR‑21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review).2020International journal of oncology
  5. Emerging landscape of circular RNAs as biomarkers and pivotal regulators in osteosarcoma.2020Journal of cellular physiology
  6. The Role of Chemotherapy in Extraskeletal Osteosarcoma: A Propensity Score Analysis of the Surveillance Epidemiology and End Results (SEER) Database.2020Medical science monitor : international medical journal of experimental and clinical research
  7. Predictors and Survival of Patients with Osteosarcoma After Limb Salvage versus Amputation: A Population-Based Analysis with Propensity Score Matching.2020World journal of surgery
  8. Mechanism of the Notch signaling pathway in enhancing the efficacy of chemotherapy drugs in osteosarcoma.2020Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  9. Association between PTEN and clinical-pathological features of osteosarcoma.2019Bioscience reports
  10. The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.2019Cancer biology & therapy
  11. Characteristics and Prognostic Factors of Patients With Osteosarcoma Older Than 60 Years From the SEER Database.2019Cancer control : journal of the Moffitt Cancer Center
  12. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b.2019Cell cycle (Georgetown, Tex.)
  13. Long non-coding RNA ZFAS1 regulates NOB1 expression through interacting with miR-646 and promotes tumorigenesis in osteosarcoma.2019European review for medical and pharmacological sciences
  14. MicroRNA-29a suppresses the invasion and migration of osteosarcoma cells by regulating the SOCS1/NF-κB signalling pathway through negatively targeting DNMT3B.2019International journal of molecular medicine
  15. MAT1 facilitates the lung metastasis of osteosarcoma through upregulation of AKT1 expression.2019Life sciences
  16. A case report of primary osteosarcoma originating from kidney.2019Medicine
  17. Evaluation of the Efficacy of Pasteurized Autograft and Intramedullary Vascularized Fibular Transfer for Osteosarcoma of the Femoral Diaphysis.2019Orthopaedic surgery
  18. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.2019World neurosurgery
  19. [Suppression of miR-30a/HMGA2-mediated autophagy in osteosarcoma cells impacts chemotherapeutics-induced apoptosis].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  20. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.2018Biochemical and biophysical research communications
  21. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  22. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  23. Identification of potential crucial genes and construction of microRNA-mRNA negative regulatory networks in osteosarcoma.2018Hereditas
  24. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.2018Journal of experimental & clinical cancer research : CR
  25. The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma.2018Molecular medicine reports
  26. The potential combinational effect of miR-34a with celecoxib in osteosarcoma.2017Anti-cancer drugs
  27. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.2017Cell cycle (Georgetown, Tex.)
  28. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  29. Actin-like protein 6A is a novel prognostic indicator promoting invasion and metastasis in osteosarcoma.2017Oncology reports
  30. Pasteurized autograft reconstruction after resection of periacetabular malignant bone tumours.2017World journal of surgical oncology
  31. Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells.2016Cancer science
  32. SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma.2016Molecular medicine reports
  33. Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression.2016Molecular medicine reports
  34. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.2016Oncotarget
  35. Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.2016Oncotarget
  36. mTOR: An attractive therapeutic target for osteosarcoma?2016Oncotarget
  37. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis.2016The International journal of biological markers
  38. miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  39. Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  40. Total femoral reconstruction with custom prosthesis for osteosarcoma.2016World journal of surgical oncology
  41. Image and pathological features of Ewing's sarcoma in the oral and maxillofacial region.2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  42. [Efficacy of reconstruction with modular endoprosthesis after resection of periacetabular malignant tumors].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  43. [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 112025

长沙有 3 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科影像/核医学科肿瘤内科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 1120232024: 0020242025: 002025

长沙有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科神经外科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科
牵头的论文1
  1. Extraosseous Ewing Sarcoma of the Cervical Esophagus: Case Report and Literature Review.2022Ear, nose, & throat journal
早期论文(2016–2020 年)3
  1. Pasteurized autograft reconstruction after resection of periacetabular malignant bone tumours.2017World journal of surgical oncology
  2. Image and pathological features of Ewing's sarcoma in the oral and maxillofacial region.2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. [Efficacy of reconstruction with modular endoprosthesis after resection of periacetabular malignant tumors].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.8%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 3320232024: 3320242025: 222025

长沙有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药诊断、微小残留病与危险分层干细胞移植
论文中的科室神经内科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. IRF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications.2026Pathology
  2. The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.2025Biochemical pharmacology
  3. Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.2025Clinical and experimental medicine免费全文
  4. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.2024Blood cancer journal免费全文
  5. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets.2024Cell death & disease免费全文
  6. Enhancing multiple myeloma staging: a novel cell death risk model approach.2024Clinical and experimental medicine免费全文
  7. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.2023Blood advances免费全文
  8. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database.2023Clinical pharmacology and therapeutics
  9. LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells.2023Current cancer drug targets
  10. CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77.2022Bioorganic chemistry
  11. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.2022Cancer letters
  12. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.2021Advances in therapy
  13. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.2021Cancer letters
  14. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.2021Clinical therapeutics
中文论文(未计入)1
  1. Diagnosis and treatment of multiple myeloma in Hunan Province.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  3. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  4. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

长沙有 4 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    分期
    II期
    开始
    2022-01
    登记号
    NCT05334823

    年龄 3 岁 至 21 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、苏州、郑州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学CAR-T 与细胞治疗

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.5%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 2220232024: 1120242025: 002025

长沙有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题免疫抑制治疗促血小板生成药物儿童
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

长沙有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题干细胞移植EB病毒与感染诱因儿童
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

长沙有 5 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

长沙有 6 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

长沙有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长沙有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 5 篇,占 7.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 2220232024: 0020242025: 002025

长沙有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 1.4%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 1120232024: 1120242025: 002025

长沙有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断影像孕期、儿童与老人
论文中的科室神经内科影像/核医学科儿科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长沙有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
    分期
    II期
    开始
    2026-10
    登记号
    NCT07222553

    年龄 2 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题头颈、眼眶与唾液腺肾脏、腹膜后与血管
论文中的科室眼科/神经眼科病理/检验科
牵头的论文1
  1. IgG4-related ophthalmic disease masquerading as ciliary body tumors and scleritis in both eyes: a case report.2023BMC ophthalmology免费全文
中文论文(未计入)2
  1. Clinical characteristics of IgG4-related disease with lung involvement in 14 patients.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. Lung adenocarcinoma misdiagnosed as IgG4-related lung disease: A case report and literature review.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD即将招募NCT07222553研究中心II期2026-10 启动
PubMed 以外找到的论文(未计入)1
  1. A Rare Case of IgG4-related Disease Manifesting as an Ulcerated Gastric Cancer Complicated With Gastric Mucormycosis2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 2220242025: 112025

长沙有 4 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除抗体与诊断常规免疫治疗
论文中的科室神经内科肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 7 篇,占 3.5%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 1120232024: 1120242025: 222025

长沙有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)诊断与铜代谢检测儿童
论文中的科室眼科/神经眼科消化/肝病科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

长沙有 3 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室儿科神经内科肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.7%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025

长沙有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 18 篇,占 1.8%。

牵头论文
18
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 7720232024: 5520242025: 222025

长沙有 6 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文18
  1. The impact of psoriasis on idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2025International journal of dermatology
  2. RTN3 regulates collagen biosynthesis and profibrotic macrophage differentiation to promote pulmonary fibrosis via interacting with CRTH2.2025Molecular medicine (Cambridge, Mass.)
  3. Molecular characterization of PANoptosis-related genes associated with immune infiltration and prognosis in idiopathic pulmonary fibrosis.2024International immunopharmacology
  4. ZCCHC8 p.P410A disrupts nucleocytoplasmic localization, promoting idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.2024Molecular medicine (Cambridge, Mass.)
  5. The prognostic role of high-density lipoprotein cholesterol/C-reactive protein ratio in idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
  6. A nonsense mutation (c.382C>T) of PARN in a patient with idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
  7. Prevalence and prognostic value of malnutrition in patients with IPF using three scoring systems.2024Respiratory medicine
  8. A novel mutation (p.Y24N) in NHP2 leads to idiopathic pulmonary fibrosis and lung carcinoma chronic obstructive lung disease by disrupting the expression and nucleocytoplasmic localization of NHP2.2023Biochimica et biophysica acta. Molecular basis of disease
  9. CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential.2023Biomolecules
  10. Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway.2023Experimental gerontology
  11. Analysis of necroptosis-related prognostic genes and immune infiltration in idiopathic pulmonary fibrosis.2023Frontiers in immunology
  12. Mitochondrial fission and bioenergetics mediate human lung fibroblast durotaxis.2023JCI insight
  13. Eupatilin inhibits pulmonary fibrosis by activating Sestrin2/PI3K/Akt/mTOR dependent autophagy pathway.2023Life sciences
  14. Integrative analysis reveals the recurrent genetic etiologies in idiopathic pulmonary fibrosis.2023QJM : monthly journal of the Association of Physicians
  15. DNA methylation in pulmonary fibrosis and lung cancer.2022Expert review of respiratory medicine
  16. Cofilin-1 promotes fibrocyte differentiation and contributes to pulmonary fibrosis.2021Biochemical and biophysical research communications
  17. Construction and validation of a bronchoalveolar lavage cell-associated gene signature for prognosis prediction in idiopathic pulmonary fibrosis.2021International immunopharmacology
  18. Associations Between Diabetes and Idiopathic Pulmonary Fibrosis: a Study-level Pooled Analysis of 26 Million People.2021The Journal of clinical endocrinology and metabolism
中文论文(未计入)1
  1. Clinical evaluation on idiopathic pulmonary fibrosis.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
早期论文(2016–2020 年)4
  1. MeCP2 epigenetically regulates alpha-smooth muscle actin in human lung fibroblasts.2020Journal of cellular biochemistry
  2. Glutaminolysis Epigenetically Regulates Antiapoptotic Gene Expression in Idiopathic Pulmonary Fibrosis Fibroblasts.2019American journal of respiratory cell and molecular biology
  3. Cigarette Smoke Extract Promotes Human Lung Myofibroblast Differentiation by the Induction of Endoplasmic Reticulum Stress.2019Respiration; international review of thoracic diseases
  4. Idiopathic Pulmonary Fibrosis: A Systemic Disease?2017Chinese medical journal
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  4. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis已终止NCT06360094研究中心II期2024-08 启动
  5. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  6. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  7. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  8. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  9. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  10. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04594707研究中心III期2021-08 启动
  11. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 3 篇,占 6.7%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

长沙有 1 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

长沙有 4 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

长沙有 5 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
牵头的论文1
  1. Fbxl3 deletion mitigates myopathy in mdx mice through upregulation of myogenin.2025Biochemical and biophysical research communications

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

长沙有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文1
  1. Decreased Expression of Sirt1 Contributes to Ocular Behçet's Disease Progression via Th17 and Th22 Response.2021Ophthalmic research
早期论文(2016–2020 年)2
  1. Comment to "Deep vein thrombosis induced by vasculitis in the Behçet's syndrome".2019Chinese medical journal
  2. Berberine exerts an anti-inflammatory role in ocular Behcet's disease.2017Molecular medicine reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 14 篇,占 1.9%。

牵头论文
14
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 5520232024: 1120242025: 222025

长沙有 7 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文14
  1. Single-Cell RNA-Sequencing Analysis Provides Insights into IgA Nephropathy.2025Biomolecules
  2. The predictive value of suPAR for glomerular segmental sclerosis lesions in renal pathology.2025Renal failure
  3. Mechanistic study of celastrol-mediated inhibition of proinflammatory activation of macrophages in IgA nephropathy via down-regulating ECM1.2024International journal of biological sciences
  4. Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis.2023BMC medical genomics
  5. EIF2α/ATF4 pathway enhances proliferation of mesangial cell via cyclin D1 during endoplasmic reticulum stress in IgA nephropathy.2023Clinical immunology (Orlando, Fla.)
  6. Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy.2023Drug design, development and therapy
  7. Clinical and pathological features of omicron variant of SARS-CoV-2-associated kidney injury.2023Journal of medical virology
  8. Changes in spectrum of biopsy-proven kidney diseases within decade: an analysis based on 10 199 cases from South China.2023Postgraduate medical journal
  9. Triptolide promotes autophagy to inhibit mesangial cell proliferation in IgA nephropathy via the CARD9/p38 MAPK pathway.2022Cell proliferation
  10. The influences of α-hemolytic Streptococcus on class switching and complement activation of human tonsillar cells in IgA nephropathy.2022Immunologic research
  11. Efficacy and indications of tonsillectomy in patients with IgA nephropathy: a retrospective study.2022PeerJ
  12. Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study.2021BMC nephrology
  13. Clinical implication of the circumferential crescents lesions in immunoglobulin A nephropathy: a single-center study of Han Chinese population.2021Human pathology
  14. Downregulation of miR‑214-3p attenuates mesangial hypercellularity by targeting PTEN‑mediated JNK/c-Jun signaling in IgA nephropathy.2021International journal of biological sciences
中文论文(未计入)2
  1. Regulatory role of the mTOR signaling pathway in autophagy and mesangial proliferation in IgA nephropathy.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  2. Clinical outcomes for kidney transplantation in 81 adults with IgA nephropathy.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
早期论文(2016–2020 年)20
  1. Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study.2020BMC nephrology
  2. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.2020Clinical immunology (Orlando, Fla.)
  3. microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy.2020Frontiers in immunology
  4. Association analysis of DNA methyltransferases in IgA nephropathy.2020International immunopharmacology
  5. Dihydroartemisinin inhibits the proliferation of IgAN mesangial cells through the mTOR signaling pathway.2020International immunopharmacology
  6. The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.2020International urology and nephrology
  7. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.2020Medical science monitor : international medical journal of experimental and clinical research
  8. Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.2019American journal of nephrology
  9. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy.2019International immunopharmacology
  10. [Clinicopathological analysis for IgA nephropathy with isolated hematuria and/or mild proteinuria].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  11. Impact of GADD34 on Apoptosis of Tonsillar Mononuclear Cells from IgA Nephropathy Patients by Regulating Eif2α Phosphorylation.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  12. Prediction of ESRD in IgA Nephropathy Patients from an Asian Cohort: A Random Forest Model.2018Kidney & blood pressure research
  13. Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a Rat Model of IgA Nephropathy.2017American journal of nephrology
  14. Serum D-dimer is a potential predictor for thromboembolism complications in patients with renal biopsy.2017Scientific reports
  15. Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.2017Scientific reports
  16. p53 induces miR199a-3p to suppress SOCS7 for STAT3 activation and renal fibrosis in UUO.2017Scientific reports
  17. Regulation of IgA Class Switch Recombination in Immunoglobulin A Nephropathy: Retinoic Acid Signaling and BATF.2016American journal of nephrology
  18. Potential diagnostic biomarkers for IgA nephropathy: a comparative study pre- and post-tonsillectomy.2016International urology and nephrology
  19. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial.2016Renal failureRCT
  20. Efficacy of triptolide on the apoptosis of tonsillar mononuclear cells from patients with IgA nephropathy.2016Renal failure
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.状态不明NCT02187900牵头方III期2014-06 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

长沙有 4 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    分期
    II期
    开始
    2026-07
    登记号
    NCT07557446

    年龄 12 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、深圳、苏州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)正在招募NCT07557446研究中心II期2026-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 2 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. [Meta Analysis of Risks of Cardiocerebral Vascular Events in Patients with Primary Biliary Cholangitis].2019Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  2. Histone Posttranslational Modifications of CD4⁺ T Cell in Autoimmune Diseases.2016International journal of molecular sciences

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

长沙有 3 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
牵头的论文1
  1. Immune profiling of premalignant lesions in patients with Peutz-Jeghers syndrome.2025United European gastroenterology journal

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中南大学湘雅二医院

Second Xiangya Hospital

长沙

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Second Xiangya Hospital of Central South University; Second Xiangya Hospital of Central South Unive; second Xiangya Hospital; Guilin Hospital of the Second Xiangya Hospital; Second Xiangya Hospital of Central-South University

提出更正下载数据